Result: rtV173L, rtL180M, rtA181V/T, rtT184G, rtS202I, rtM204V/I, rtN236T and rtM250V were first studied and then, others residues with changes present in at least two patients were further considered.
Result: Overall, only 1 patient who had never received 3TC or FTC for HBV- or HIV-infection presented M204V and L180M mutations.
Result: Th
Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients.
Abstract: An additional five patients developed entecavir genotypic resistance, with prior occurrence of lamivudine-resistant mutation (L180 M +- M204 V/I).
Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B.
Abstract: Patient 2 had substitutions of L80V, W153Q, and L180M.
Abstract: RESULTS: Among the six patients with LAM failure, the analysis of 100 clones from patient 1 revealed the substitutions L180M in 1% of clones and V173L in 2% of clones.
Result: Among six patients with LAM failure, cloning and sequencing data on the RT region of HBV revealed that LAM resistance mutation, L180M or M204V/I substitutions, pre-existed in patient 1, 2, 5, and 6, albeit a small percentage (1% to 2%).
Result: At 6 months of LAM therapy, quasispecies variants bearing LAM resistance mutations, M204V/I+L180M, appeared in all six patien
Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients.
Result: Of 24 cases with the rtM204I mutation, three had co-dominant rtM204I and rtL180M mutations.
Result: One patient had a mixed pattern of rtM204I/V and rtL180M mutations.
Discussion: Resistant mutations were rtM204I and/or rtM204V and/or rtL180M; these are well-known antiviral resistant mutations in HBV DNA against lamivudine and telbivudine.
[High-throughout detection and analysis of drug-resistance gene mutation for 2465 cases with chronic hepatitis B in Shenzhen].
PMID: 23855124
2013
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: The frequency of Lamivudine related mutation was the highest (42.96%), especially on rtL180M (14. 72%), rtL204I (18. 50%), rtL204V (9. 74%).
Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Abstract: LMV-resistant mutations (rtL180M and/or rtM204VI) were detected in 9 patients before ETV treatment and not in another 5 patients before and after the treatment.
[Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
Abstract: In five of nine samples primary and compensatory multiple mutations (L180M + M204I in one sample, L80I + L180M + M204I in two samples, L80I/V + M204I in one sample) and primary single mutations associated with LVD resistance (M204I/V) in four samples were detected by Inno-Lipa HBV DRv2.
Abstract: Multiple mutations that comprise L180M + M204I in four and L180M + M204V in one sample and single mutations (M204I) in three samples were identified by SEQ.
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Abstract: Primary drug resistance mutations (rtV173L + rtL180M + rtM204V) to lamivudine and telbivudine and a compensatory mutation (rtQ215H) to lamivudine and adefovir were described in the HBV pol gene sequence.
HBV mutation literature information.
PMID: 
2013
Iranian journal of microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT